Two Sigma Advisers’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-136
Closed -$90.8K – 1649
2025
Q4
$90.8K Buy
+136
New +$68.4K ﹤0.01% 2238
2024
Q3
– Sell
-468
Closed -$70.2K – 2480
2024
Q2
$70.2K Sell
468
-18
-4% -$3.25K ﹤0.01% 2339
2024
Q1
$103K Sell
486
-64
-12% -$15.9K ﹤0.01% 2302
2023
Q4
$116K Sell
550
-110
-17% -$22K ﹤0.01% 2311
2023
Q3
$148K Sell
660
-296
-31% -$77.3K ﹤0.01% 2153
2023
Q2
$288K Sell
956
-1,069
-53% -$333K ﹤0.01% 1991
2023
Q1
$632K Sell
2,025
-119
-6% -$23.3K ﹤0.01% 1845
2022
Q4
$273K Sell
2,144
-155
-7% -$25.9K ﹤0.01% 2096
2022
Q3
$611K Sell
2,299
-255
-10% -$97.1K ﹤0.01% 1757
2022
Q2
$1.13M Buy
2,554
+22
+0.9% +$15.6K ﹤0.01% 1529
2022
Q1
$3.13M Sell
2,532
-52
-2% -$70.8K 0.01% 1020
2021
Q4
$6.52M Buy
2,584
+2,391
+1,239% +$14.6M 0.02% 656
2021
Q3
$3.53M Buy
193
+146
+311% +$2.32M 0.01% 954
2021
Q2
$498K Sell
47
-9
-16% -$75.5K ﹤0.01% 1936
2021
Q1
$404K Buy
56
+6
+12% +$43.2K ﹤0.01% 2095
2020
Q4
$275K Buy
+50
New +$443K ﹤0.01% 2070

Other funds holding IRLA

Two Sigma Advisers's IRLA Position: Q1 2026 in Review

Two Sigma Advisers sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 136 shares — an estimated $90.8K sold.

Two Sigma Advisers first reported a position in IRLA in Q4 2020 and held it in 16 quarters. The position peaked at $6.52M in Q4 2021. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

  • Two Sigma Advisers reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 136 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $90.8K.
  • Two Sigma Advisers first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 16 quarters.
  • Two Sigma Advisers's IRulya Therapeutics Inc. Common Stock position peaked at $6.52M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.